+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Stuttering - Epidemiology Forecast - 2032

  • PDF Icon

    Drug Pipelines

  • 48 Pages
  • March 2022
  • Region: Global
  • DelveInsight
  • ID: 5525782
This ‘Stuttering- Epidemiology Forecast-2032' report delivers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Stuttering Disease Understanding


Childhood-onset fluency disorder, also known as stuttering or stammering, is a common multifactorial speech disorder. It is a disruption in the fluency of verbal expression characterized by involuntary, audible, or silent repetitions or prolongations of sounds or syllables. These are not readily controllable and may be accompanied by other movements and by emotions of negative nature such as fear, embarrassment, or irritation, and are normally seen with recurrent prolongations, reverberations, or blocks of sounds, syllables, phrases, or words.

As it is a disorder in the fluency of speech, in addition to involuntary repetition and prolongation of sounds and syllables, there is also “secondary stuttering behavior,” which occurs as a response to the core stuttering behavior. These can be further explained by the example of “flight behaviors”, varying from choosing synonyms for the feared words to opting for social isolation to avoid speaking and concealing the stuttering out of anxiety, frustration, and shame. There are also “fight behaviors” varying from unnatural eye-blinking to involuntary movement of the extremities.

Stuttering arises, in general, before age 6, usually between 2.5 and 4 years of age. The most common form of stuttering is referred to as developmental stuttering. This may be contrasted with other forms of stuttering, which, for instance, arise from a neurological condition, trauma or emotional stress. Clinical diagnosis typically measures the rates of stuttering dysfluencies while reading or during free speech and can include the rate of ancillary symptoms, sometimes known as struggle behaviors, during speech.

Stuttering Diagnosis


Stuttering is usually diagnosed by a speech-language pathologist (SLP), a health professional trained to test and treat individuals with voice, speech, and language disorders. The SLP will consider a variety of factors, including the following:

  • Child's case history (such as when the stuttering was first noticed and under what circumstances)
  • An analysis of the child's stuttering behaviors
  • An evaluation of the child's speech and language abilities and the impact of stuttering on their life
When evaluating a young child for stuttering, a speech-language pathologist will try to determine if the child is likely to continue their stuttering behavior or outgrow it. To determine this difference, the SLP will consider such factors as the family's history of stuttering, whether the child's stuttering has lasted 6 months or longer, and whether the child exhibits other speech or language problems.

Some aspects of stuttering are apparent, while others are not. A speech-language pathologist (SLP) can make a comprehensive and reliable diagnosis. Stuttering is more than disfluencies, so it is important to see an SLP for testing.

Different guidelines and expert committees have designated different parameters for classification of Stuttering.

Stuttering Epidemiology Perspective


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Stuttering, diagnosed prevalent cases of Stuttering and gender-specific diagnosed prevalent cases of Stuttering, scenario of Stuttering in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Stuttering Detailed Epidemiology Segmentation

  • Total prevalent cases of stuttering in the 7MM were found to be approximately 3,981,012 in 2021. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
  • Among 7MM, the United States has the highest prevalent cases of stuttering with 1,636,434 cases in 2021.
  • The total diagnosed prevalent cases of stuttering in the 7MM were observed to be 878,024 in 2021. These cases are expected to increase during the study period (2019-2032).
  • A total of 409,108 diagnosed prevalent cases of stuttering were recorded in the US in 2021, these cases are expected to rise at a CAGR of 0.8% for the study period (2019-2032).
  • Among the European countries, Germany had the highest diagnosed prevalent population of Stuttering with 88,573 cases, followed by the UK with 67,196 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In Japan, 132,528 diagnosed prevalent cases of stuttering were recorded in the year 2021.
  • As per the publisher's assessment, for stuttering, the gender-specific distribution of the disease suggests male predominance with 658,518 cases while females were at a lower count with 219,506 cases in the 7MM.

Scope of the Report

  • The report covers the descriptive overview of stuttering, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of stuttering.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM, prevalent cases of stuttering, diagnosed prevalent cases of stuttering and gender-specific diagnosed prevalent cases of stuttering.

Report Highlights

  • 11-Year Forecast of Stuttering
  • The 7MM Coverage
  • Total prevalent cases of stuttering
  • Diagnosed prevalent cases of stuttering
  • Gender-specific diagnosed prevalent cases of stuttering

Key Questions Answered

  • What are the disease risk and burdens of stuttering?
  • What is the historical stuttering patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of stuttering at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population about stuttering?
  • Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of stuttering during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to Buy


The stuttering report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the 7MM stuttering epidemiology forecast.
  • The stuttering epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The stuttering epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Table of Contents

1. Key Insights2. Report Introduction
3. Stuttering Patient Overview at a Glance
3.1. Patient Share (%) Distribution of Stuttering in 2019
3.2. Patient Share (%) Distribution of Stuttering in 2032
4. Executive Summary of Stuttering
5. Disease Background and Overview: Stuttering
5.1. Introduction of Stuttering
5.2. Types of Stuttering
5.3. Risk Factors of Stuttering
5.4. Signs and Symptoms of Stuttering
5.5. Etiology and Causes of Stuttering
5.6. Pathophysiology of Stuttering
5.7. Diagnosis of Stuttering
5.7.1. Diagnostic Guidelines
5.7.1.1. WHO ICF Framework
5.7.1.2. German Guidelines on Fluency Disorders Based on ICF Mode
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.3. Assumptions and Rationale: 7MM
6.4. Total Prevalent Cases of Stuttering in the 7MM
6.5. Total Diagnosed Prevalent Cases of Stuttering in the 7MM
6.6. The United States
6.6.1. Prevalent Cases of Stuttering in the United States
6.6.2. Diagnosed Prevalent Cases of Stuttering in the United States
6.6.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in the United States
6.7. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
6.7.1. Germany
6.7.1.1. Prevalent Cases of Stuttering in Germany
6.7.1.2. Diagnosed Prevalent Cases of Stuttering in Germany
6.7.1.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany
6.7.2. France
6.7.2.1. Prevalent Cases of Stuttering in France
6.7.2.2. Diagnosed Prevalent Cases of Stuttering in France
6.7.2.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in France
6.7.3. Italy
6.7.3.1. Prevalent Cases of Stuttering in Italy
6.7.3.2. Diagnosed Prevalent Cases of Stuttering in Italy
6.7.3.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy
6.7.4. Spain
6.7.4.1. Prevalent Cases of Stuttering in Spain
6.7.4.2. Diagnosed Prevalent Cases of Stuttering in Spain
6.7.4.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain
6.7.5. UK (United Kingdom)
6.7.5.1. Prevalent Cases of Stuttering in UK
6.7.5.2. Diagnosed Prevalent Cases of Stuttering in UK
6.7.5.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in UK
6.8. Japan
6.8.1. Prevalent Cases of Stuttering in Japan
6.8.2. Diagnosed Prevalent Cases of Stuttering in Japan
6.8.3. Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan
7. Patient Journey8. KOL Views
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities11. Disclaimer12. About the Publisher
List of Tables
Table 1: Summary of Stuttering, Market, and Epidemiology (2019-2032)
Table 2: Risk Factor Chart
Table 3: Symptoms of Stuttering and Distinction From Normal Speech Dysfluencies
Table 4: Diagnostic Instruments for stuttering
Table 5: Total Prevalent Cases of Stuttering in the 7MM, in ‘000' (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of Stuttering in the 7MM, in ‘000' (2019-2032)
Table 7: Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Table 8: Diagnosed Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Table 9: Gender-specific Diagnosed Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Table 10: Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Table 11: Diagnosed Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Table 12: Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Table 13: Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Table 14: Diagnosed Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Table 15: Gender-specific Diagnosed Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Table 16: Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Table 17: Diagnosed Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Table 18: Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Table 19: Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Table 20: Diagnosed Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Table 21: Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Table 22: Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Table 23: Diagnosed Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Table 24: Gender-specific Diagnosed Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Table 25: Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
Table 26: Diagnosed Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
Table 27: Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
List of Figures
Figure 1: Subtypes of Fluency Disorders
Figure 2: Types of Stutter
Figure 3: Primary Behaviors of Stuttering
Figure 4: Etiology of Stuttering
Figure 5: Causes of Stuttering
Figure 6: Total Prevalent Cases of Stuttering in the 7MM, in ‘000' (2019-2032)
Figure 7: Total Diagnosed Prevalent Cases of Stuttering in the 7MM, in ‘000' (2019-2032)
Figure 8: Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Figure 9: Diagnosed Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Figure 10: Gender-specific Diagnosed Prevalent Cases of Stuttering in the US, in ‘000' (2019-2032)
Figure 11: Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Figure 12: Diagnosed Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Figure 13: Gender-specific Diagnosed Prevalent Cases of Stuttering in Germany, in ‘000' (2019-2032)
Figure 14: Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Figure 15: Diagnosed Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Figure 16: Gender-specific Diagnosed Prevalent Cases of Stuttering in France, in ‘000' (2019-2032)
Figure 17: Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Figure 18: Diagnosed Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Figure 19: Gender-specific Diagnosed Prevalent Cases of Stuttering in Italy, in ‘000' (2019-2032)
Figure 20: Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Figure 21: Diagnosed Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Figure 22: Gender-specific Diagnosed Prevalent Cases of Stuttering in Spain, in ‘000' (2019-2032)
Figure 23: Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Figure 24: Diagnosed Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Figure 25: Gender-specific Diagnosed Prevalent Cases of Stuttering in the UK, in ‘000' (2019-2032)
Figure 26: Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
Figure 27: Diagnosed Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
Figure 28: Gender-specific Diagnosed Prevalent Cases of Stuttering in Japan, in ‘000' (2019-2032)
Figure 29: Patient Journey